Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or centrifugation to remove cellular debris. The clarified viral suspension undergoes purification steps such as chromatography and ultrafiltration to isolate the virus. For inactivated vaccines, the purified virus is chemically treated, often with formaldehyde or β-propiolactone, to render it non-infectious while maintaining antigenicity.
In bacterial vaccine production, bacterial strains are cultured in nutrient-rich media under tightly regulated conditions. Post-cultivation, bacterial cells are harvested using centrifugation or filtration. Depending on the vaccine type, bacterial toxins can be isolated and inactivated with formaldehyde to form toxoids, or entire bacterial cells can be heat-inactivated for killed vaccines. The antigenic components are then subjected to purification steps tailored to the specific pathogen and vaccine formulation.
Following antigen purification, the formulation stage involves combining the antigen with adjuvants to enhance immune response, stabilizers to maintain vaccine potency during storage, and preservatives to prevent microbial contamination. This formulation undergoes sterile filtration before being filled into vials or syringes.
Downstream processes also include rigorous quality control protocols at various stages. These assessments include sterility testing, potency assays, identity verification, and purity analysis through methods like ELISA, SDS-PAGE, and HPLC. Each batch is tested to comply with regulatory standards.
Finally, vaccines are packaged under aseptic conditions in unit doses or multi-dose containers. Packaging includes appropriate labeling with batch numbers, expiration dates, and storage instructions. Cold chain logistics are implemented to preserve vaccine stability from production to administration.
Vaccine production begins by cultivating pathogens, such as viruses or bacteria, to generate antigens.
For viral vaccines, particularly whole virus vaccines, host cells, such as mammalian cells, are grown in bioreactors and infected with the virus.
The virus replicates inside host cells, which are then lysed to release the viral particles.
The virus-containing mixture is clarified to remove cell debris and then purified.
Once purified, the virus may be maintained in an attenuated form or inactivated by killing with heat, chemicals like formaldehyde, or radiation, depending on the vaccine type.
For bacterial vaccines, bacteria are cultured in nutrient-rich media under controlled conditions.
The cells are then harvested and separated by centrifugation.
For whole-cell bacterial vaccines, cells are collected and inactivated by heat or chemicals.
For toxoid vaccines, secreted toxins in the supernatant are harvested and inactivated.
The resulting antigens are then formulated with adjuvants and stabilizers to produce the final vaccine.
繁體中文
